Adeshwar Meditex (543309)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter profitable: ₹30 Cr sales and ₹1 Cr net profit
• Trailing P/E of 14.64 is undemanding for a going concern
• ROCE of 8.27% is positive, indicating some return on capital employed
• Market cap of ₹40 Cr leaves room for niche specialisation

Concerns

• Sales growth of -26.50% and profit growth of -18.89% show continuous shrinkage
• Piotroski F-Score of 3/9 points to weak financial health and operational efficiency
• No dividend yield, so investors must rely entirely on capital gains
• Critical data absent: book value, ROE, debt/equity, and promoter holding

AI Analysis

At ₹27.50, Adeshwar Meditex is a ₹40 crore microcap with a trailing P/E of 14.64. But a low multiple alone never made a good investment. Sales have fallen 26.50% and profits are down 18.89%. When the top line is shrinking this fast, I need a large margin of safety, not just a cheap-looking number. The ROCE is only 8.27%, which tells me capital is not being deployed with exceptional efficiency. Worse, the Piotroski F-Score is 3/9—a clear warning sign of weak financial health and operational strain. I also have no book value, no ROE, no debt-to-equity ratio, and no promoter holding data. Graham taught me to invest only when I can understand the balance sheet and verify management's alignment. Here, critical information is missing, and in the absence of information, I must assume risk, not opportunity. The latest quarter shows sales of ₹30 Cr and a net profit of ₹1 Cr, so the business is not dead. But one profitable quarter does not make a turnaround. And at the top of the 52-week range, the market is already celebrating while sales and profits are declining. There is no dividend, so all returns depend on price appreciation—a dangerous position for a shrinking company. This has the look of a speculative bounce, not a value investment. If revenue stabilises, ROCE improves, and the balance sheet is disclosed, I could revisit. Until then, the figures fail my test. As I always say: it is better to miss an opportunity than to lose capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer